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Abstract Tumor-speciWc gene products, such as can-
cer/testis (CT) antigens, constitute promising targets
for the development of T cell vaccines. Whereas CT
antigens are frequently expressed in melanoma, their
expression in colorectal cancers (CRC) remains poorly
characterized. Here, we have studied the expression of
the CT antigens MAGE-A3, MAGE-A4, MAGE-A10,
NY-ESO-1 and SSX2 in CRC because of the presence
of well-described HLA-A2-restricted epitopes in their
sequences. Our analyses of 41 primary CRC and 14
metastatic liver lesions conWrmed the low frequency of
expression of these CT antigens. No increased expres-
sion frequencies were observed in metastatic tumors
compared to primary tumors. Histological analyses of
CRC samples revealed heterogeneous expression of
individual CT antigens. Finally, evidence of a naturally
acquired CT antigen-speciWc CD8+ T cell response
could be demonstrated. These results show that the
expression of CT antigens in a subset of CRC patients
induces readily detectable T cell responses.
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Abbreviations
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Introduction
Colon cancer is one of the most frequent cancers in
aZuent countries. Its prognosis remains poor, with 5-
year survival rates approximating 40% [1], because
the diagnosis is frequently made at an advanced stage
of the disease. Although 80% of colorectal cancer
(CRC) patients undergo a complete macroscopic
removal of their malignant lesions by surgical resec-
tion, a signiWcant proportion of them recur, usually as
a result of already disseminated micrometastases at
the time of surgery. Among the new approaches tar-
geting these disseminated tumor cells, the use of
tumor-speciWc cytolytic T lymphocytes (CTL) are of
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tumor-inWltrating T lymphocytes has been found to
be associated with prolonged survival [2–4]. Even if
the speciWcities of these T lymphocytes have not yet
been elucidated, in vivo stimulation of CRC-speciWc
T lymphocytes could be envisaged as adjuvant ther-
apy to tumor resection.
Over the last 15 years, many tumor-associated anti-
gens recognized speciWcally by CD8+ T lymphocytes
have been identiWed and characterized. These anti-
gens are commonly classiWed into four categories:
cancer/testis (CT) antigens (aka cancer/germline or
shared tumor-speciWc antigens), diVerentiation anti-
gens, overexpressed antigens and antigens resulting
from patient-speciWc point mutations. In CRC, CT
antigens are particularly interesting targets because
they are predicted to be expressed speciWcally by the
tumor cells and not by the adjacent normal epithelial
cells. Such speciWcity is not expected for antigens of
the second and third category and may therefore
reduce their usefulness in the immunotherapeutic
treatment of CRC because of the side eVects associ-
ated with the potential destruction of normal colon
epithelia. Unfortunately, contrary to metastatic mela-
noma in which CT genes are expressed at frequencies
ranging from 20 to 70%, CRC is generally considered
as a poor CT antigen expresser since less than 10% of
all analyzed CT genes are expressed at frequencies
exceeding 20% [5]. Despite the rare expression of
most CT genes, it remains unclear if the expression of
one or the other CT antigen can elicit spontaneous
T cell responses in CRC patients, as is the case for
melanoma patients [6–9].
In this work, we monitored the expression of CT
antigens in primary lesions and liver metastases of
51 CRC patients. We focused our analysis on CT
antigens for which HLA-A2-restricted peptides had
been previously identiWed. Expression was analyzed
by semi-quantitative PCR and, in selected patients, by
immunohistochemical staining of paraYn-embedded
tumor sections. Our results indicate that CT antigens
are rarely expressed in primary and metastatic colo-
rectal tumors. However, in those patients that showed
CT antigen expression in the primary CRC, the
expression was maintained in the metastases. Finally,
two patients bearing NY-ESO-1- and MAGE-A3-
positive tumors (detected by RT-PCR and immuno-
histochemistry), respectively, were found to have
detectable frequencies of circulating CD8+ T lympho-
cytes reactive against these antigens. Taken together,
our results indicate that spontaneous T cell responses
can be elicited by the expression of CT antigens in
CRC lesions.
Materials and methods
Patients
Peripheral blood mononuclear cell (PBMC) and tumor
samples of CRC patients were obtained after informed
consent. The study protocol was approved by the
Ludwig Institute for Cancer Research ethical review
committee, as well as by the medical and ethical com-
mittees of the University Hospital (Lausanne, Switzer-
land). The patients’ HLA haplotype was determined
by serological typing. All patients were operated
according to standard procedures and none of them
was treated with preoperative neoadjuvant therapy.
There were 4 stage I (T1–T2, N0, M0), 9 stage II
(T3–T4, N0, M0), 4 stage III (any T, N1, M0) and 37
stage IV (any T, any N, M1) patients according to the
TNM classiWcation, sixth edition (2002).
Tissue preparation
Tissue samples from normal colonic mucosa, normal
liver, colon cancer and metastatic colon cancer were
obtained at the time of surgical resection. Tissue frag-
ments were cut into small fragments and immediately
frozen in liquid nitrogen. Samples were stored at
¡80°C until the time of mRNA extraction. In parallel,
tissue samples were also embedded in paraYn and
used for pathological analysis (TNM, sixth edition
2002) and tumor staging.
Isolation of mRNA and synthesis of cDNA
Frozen fragments were processed using Qiagen RNA-
easy MiniKit (Qiagen, Hilden, Germany). In brief, fro-
zen material was weighed and mechanically dissociated
by Polytron (Kinematica AG, Newark, NY, USA) in
RLT buVer following the manufacturer’s instructions.
The samples were then treated with DNAse I (Qiagen)
to remove genomic DNA. PuriWed mRNA was quanti-
Wed by spectrophotometry and stored at ¡80°C.
mRNA was reverse-transcribed to cDNA using Qiagen
RT-PCR Kit (Qiagen), starting from 4 g mRNA for
each sample.
Semi-quantitative PCR
The sequences of primer pairs used to amplify each CT
antigen have been described previously [10–12]. Inter-
sample mRNA content was evaluated by quantitative
real-time PCR on the house-keeping gene -actin
(primers: 5-GGCATCGTGATGGACTCCG -3; 5-
GCTGGAAGGTGGACAGCGA-3) associated with123
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reuz, Switzerland). Reactions were performed in a
LightCycler 1.5 Instrument following manufacturer’s
instructions (Roche Applied Science). Relative abun-
dance of -actin mRNA did not vary by more than
threefold among all samples tested (data not shown).
CT genes were analyzed by semi-quantitative PCR on
serial Wvefold dilutions of cDNA. HotStarTaq DNA
Polymerase (Qiagen) was used in all reactions follow-
ing the manufacturer’s instructions, with the exception
of NY-ESO-1, which was performed using Taq DNA
polymerase and the addition of Q solution (Qiagen).
Thermocycling conditions were the following:
MAGE-A3 (annealing temp 66°C, 31 cycles); MAGE-
A4 (annealing temp 68°C, 33 cycles); MAGE-A10
(annealing temp 55°C, 39 cycles); NY-ESO-1 (anneal-
ing temp 60°C, 37 cycles); SSX2 (annealing temp 62°C,
40 cycles). All reactions were performed in a T3 ther-
mocycler (Biometra, Göttingen, Germany). Expres-
sion was scored positive when a band was visible on
agarose gel stained with ethidium bromide at any of
the three dilutions. Absence of detectable band was
scored as negative.
Immunohistochemistry
Tumor samples were Wxed in 4% buVered formalin,
embedded in paraYn and stained with hematoxylin
and eosin. Additional sections were studied by immu-
nohistochemistry with two pan-MAGE-A monoclonal
antibodies (clones 57B and 6C1) and the monoclonal
anti-NY-ESO-1 antibody (clone D8.38) [13, 14]. Par-
aYn-embedded slides of testicular seminoma were
used as positive controls. Immunohistochemistry slides
were developed using Ultrateck-Peroxidase kit (Beck-
man Coulter, Fullerton, USA).
Isolation and expansion of peripheral blood 
lymphocytes
Blood samples from patients LAU846 and LAU911
were obtained before surgery. Ficoll-Paque centri-
fuged PBMC were cryopreserved in RPMI 1640 (Invi-
trogen, Basel, Switzerland) supplemented with 40%
FCS, and 10% DMSO. In CTL induction assays,
PBMC were thawed and plated in 96 U-bottom plates
at 2 £ 105 cells/well in the presence of 10 M peptide
and 1 g/ml 2-microglobulin (Sigma, Oakville, Can-
ada), in RPMI 1640 supplemented with 8% pooled
human serum, Penicillin/Streptomycin, HEPES and 2-
mercaptoethanol (culture media), as described else-
where [15]. Seventy-two hours later, 1,000 IU/ml IL-2
was added to cultures and the culture media was
replaced every second day until the day of functional
analysis (day 10).
Tetramer analysis
Cytolytic T lymphocytes generated from PBMC were
stained with Phycoerythrin-labeled HLA-A2/peptide
tetramers. Cells (106) were incubated with tetramers
(10 g/ml, 60 min at room temperature) and then with
anti-human CD8 mAb (30 min, 4°C). Dead cells were
electronically excluded by propidium-iodide staining.
CD8+ T cells (5 £ 105 cells per sample) were analyzed
by Xow cytometry on a FACScan machine using Cell-
Quest software (BD Biosciences, San Jose, CA).
IFN- ELISPOT assay
Human IFN- ELISPOT PVDF-Enzymatic kit (Dia-
clone, Besançon, France) was used according to the
manufacturer’s instructions. Human IFN--speciWc
capture mAb were adsorbed on MultiScreen-HA Filter
96 well Plates (Millipore, Billerica, MA, USA) for 16 h
at 4°C and blocked with RPMI supplemented with
10% FCS for 60 min at 37°C. PBMC stimulated in vitro
with 10 M peptide and IL-2 (1,000 IU/ml) for 9 days
were seeded in each well (2 £ 105/well) in six replicates
and stimulated with 10 M peptide. As positive con-
trol, an aliquot of the cells was stimulated with 1 g/ml
PMA (Sigma) and 0.25 g/ml Ionomycin (Sigma).
Plates were incubated for 18 h at 37°C in 5% CO2,
washed, and incubated with biotinylated anti-IFN-
detection mAb followed by alkaline phosphatase-
conjugated streptavidin. Spots were developed by adding
peroxidase substrates (5-bromo-4,3-indolyl phosphate
and nitroblue tetrazolium) and counted using the auto-
mated image analysis system Bioreader 2000 (BIO-
SYS, Karben, Germany).
Results
CT gene expression proWle in patients with primary 
colon cancer
On the basis of a recent survey, it was found that most
CT antigens that are encoded by genes located on
chromosome X were rarely expressed in colon cancers
whereas they were frequently expressed in metastatic
melanomas [5, 16]. Because it is not known if the
sporadic expression of CT antigens in CRC could nev-
ertheless elicit antigen-speciWc T cell responses we
screened a series of CRC patients for the expression of
CT antigens. We focused our analysis on MAGE-A3,123
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because each contained at least one well-deWned HLA-
A2-restricted T cell epitope.
Samples from 41 patients with primary CRC and 14
patients with metastatic liver lesions were collected.
For 30 of the 41 patients, we obtained fresh tissue
from the tumor and from the normal adjacent colonic
mucosa. Moreover, for 6 of these patients, we were
able to collect tissue both from the primary and
hepatic metastatic tumors. The median age of the
patients was 66 years, ranging from 43 to 91 years.
None of them received chemotherapy or radiotherapy
prior to surgery.
RNA was extracted from each individual sample
and reverse-transcribed. The expression of CT genes
was assessed by semi-quantitative PCR. cDNA from
testis and the CT-gene positive melanoma cell line
SK-MEL-37 were used as positive controls. Normal
colon tissue was used as negative control. To evaluate
the amount of RNA extracted from each sample, we
performed quantitative PCR on -actin (data not
shown).
As shown in Table 1, the expression of the diVer-
ent CT genes in primary CRC varied between 2% for
MAGE-A10 and 15% for MAGE-A4. The frequency
of CRC patients expressing MAGE-A3 was 13 and
4% for NY-ESO-1 and SSX2. The majority of tumors
did not express any CT gene, conWrming the previous
Wndings that colon cancer is a poor CT antigen
expresser [5, 16]. However, co-expression of several
CT genes was observed in patients LAU846,
LAU888 and LAU911 (Fig. 1). Contrary to bladder
carcinoma [17], we did not detect any correlation
between the neo-expression of the CT genes and
tumor diVerentiation, although the number of posi-
tive tumors was probably too small to draw Wrm con-
clusions.
Comparison of the CT gene expression proWle between 
primary and metastatic tumors
Previous reports suggested that, in melanoma, the
frequency of expressed genes was increased during
progression from primary to metastatic disease [18].
Thus, the low frequency of CT antigen expression
in CRC could be due to the fact that, contrary to mel-
anoma, the majority of CRC tumor specimens are
isolated from primary lesions [5]. To test this hypoth-
esis, we screened samples obtained from liver metas-
tases of 14 CRC patients. Importantly, for six of
those specimens, we also had access to the corre-
sponding primary tumor, allowing a comparison of
the expression pattern within the same patient. The
results obtained in patient LAU846 (Fig. 1) are rep-
resentative of what was observed with the samples of
the other Wve patients. Overall, the expression of
MAGE-A3, -A4 and -A10, NY-ESO-1 and SSX2 was
not more frequent in the hepatic metastatic lesions
Fig. 1 Analysis of CT gene expression by semi-quantitative RT-
PCR. Expression of MAGE-A3, MAGE-A4, MAGE-A10, NY-
ESO-1, SSX2 and the housekeeping gene -actin in normal and
tumor samples of LAU852 and LAU911 as well as tumor and
metastatic samples of LAU846 was analyzed by RT-PCR. For
each tissue sample, PCR was performed on serial Wvefold dilu-
tions of the cDNA. The cDNA prepared from human testis and
the melanoma cell line SK-MEL-37 were used as positive con-
trols. Arrows indicate the speciWc product and stars genomic con-
tamination
*
*
MAGE-A3
MAGE-A4
β-actin
MAGE-A10
NY-ESO-1
SSX2
SK-M
EL-37
Testi
s
LAU8
52no
LAU8
52tu
LAU8
46tu
LAU8
46me
t
LAU9
11no
LAU9
11tu
Table 1 CT gene expression frequencies in colon cancer primary
tumors
Antigen n Events Frequency (%)
MAGE-A3 45 6 13
MAGE-A4 48 7 15
MAGE-A10 48 1 2
NY-ESO-1 48 2 4
SSX2 45 2 4123
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conclude that the low expression of CT gene in CRC
cannot be ascribed to the stage of the tumor but
rather reveal intrinsic diVerences between melanoma
and CRC.
Immunohistochemical analysis of CT antigens in CRC 
lesions
For some of the patients that were found to express
one or several CT genes by RT-PCR, we performed
immunohistochemical analysis of their tumor speci-
mens. ParaYn-embedded histological slides of tumor
samples located next to the ones used for RT-PCR
were stained with monoclonal antibodies raised
against MAGE-A3 (clone 57B), MAGE-A1 (clone
6C1) and NY-ESO-1 (clone D8.38). These antibodies
have been extensively characterized earlier and cross-
reactivity of the two anti-MAGE-A clones against
other members of the MAGE-A family has been
described [13].
Patient LAU846, LAU852 and LAU911 were
found to express MAGE-A3 and MAGE-A4 in their
tumors by RT-PCR. Immunostaining of the primary
tumor specimens of these patients with mAb 57B
conWrmed the expression of MAGE-A3 detected by
PCR (Fig. 2). A strong staining was observed for
MAGE-A3 in testicular seminoma, whereas the
intensity of the staining was lower in CRC, suggest-
ing that the antigen was expressed at low levels.
Staining with mAb 6C1 showed similar results for
patients LAU846 and 852. Expression appeared
much stronger in the samples from patient LAU911,
possibly due to the strong expression of MAGE-
A10, against which this mAb cross-reacts [13]. With
both mAb, the staining was heterogeneous in the
carcinomatous glands and predominantly in the
nucleus of the tumor cells. Positive NY-ESO-1 stain-
ing was also found for patient LAU911. This result is
in agreement with the expression detected by RT-
PCR.
Table 2 CT gene expression frequencies in colon cancer metas-
tases
Antigen n Events Frequency (%)
MAGE-A3 12 1 8
MAGE-A4 14 2 14
MAGE-A10 14 0 0
NY-ESO-1 10 1 10
SSX2 10 0 0
Fig. 2 Detection of CT antigen expression in CRC by immuno-
histochemistry. Sections of the primary CRC tumors isolated
from the CT antigen-positive patients LAU846, LAU852 and
LAU911 were stained with mAb anti-MAGE (57B and 6C1) and
anti-NY-ESO-1 (D8.38). As positive control, sections from CT
antigen-positive testicular seminoma were stained with the same
set of antibodies. Hematoxylin/eosin staining of the individual
sections is shown at lower magniWcation. Filled arrows indicate
an example of positive stained tumor cell. Empty arrows indicate
an example of negative stained tumor cell. The region shown at
higher magniWcation after mAb staining is boxed 123
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Having demonstrated expression of MAGE-A3,
MAGE-A10 and NY-ESO-1 in patients LAU846 and
LAU911, we determined if these patients displayed
evidence of naturally developed CD8+ T cell responses
against any of the three CT antigens. PBMC from
patient LAU911 (HLA-A1, -A2, -B51, -B57) were
stimulated once with the HLA-A2-restricted NY-ESO-
1157–165 [19], MAGE-A3112–120 [20] or MAGE-A10254–262
peptides [21] and enumerated, after 10 days of culture,
with HLA-A2 tetramers incorporating the correspond-
ing peptides. As shown in Fig. 3a, 0.1% speciWc CD8+ T
cells were detected by the A2NY-ESO-1 tetramer in
patient LAU911. MAGE-A3112–120- and MAGE-
A10254–262-reactive CD8
+ T cells remained undetect-
able in patients LAU919, LAU911, LAU942, LAU987
and LAU919, LAU911, respectively. As negative con-
trol, we performed the same experiment using PBL
obtained from patient LAU919 (HLA-A2+ MAGE-
A3¡ MAGE-A10¡ NY-ESO-1¡) but we did not detect
any tetramer staining.
Fig. 3 T cell responses in CT 
antigen-positive CRC pa-
tients. a Detection of CT anti-
gen-speciWc T cells in HLA-
A2 patients by A2 tetramers. 
PBMC from patients LAU919 
(MAGE-A3¡ MAGE-A10¡ 
NY-ESO-1¡), LAU911 
(MAGE-A3+ MAGE-A10+ 
NY-ESO-1+), LAU942 and 
987 (MAGE-A3+) were stim-
ulated individually in vitro 
with peptides MAGE-A3112–
120, MAGE-A10254–262 and 
NY-ESO-1157–165 (LAU919 
and LAU911) or only 
MAGE-A3112–120 (LAU942 
and LAU987). At day 10, pep-
tide-speciWc CD8+ T cells 
were detected by Xow 
cytometry with A2 tetramers 
incorporating the correspond-
ing peptides. Dead cells were 
excluded by PI staining. 
b IFN- ELISPOT assay of in 
vitro stimulated PBMC of 
patient LAU846. PBMC 
were stimulated once in vitro 
with peptides NY-ESO-1-
ORF246–54 and MAGE-
A3167–176 and analyzed at day 
10. Autologous cells were 
used as antigen-presenting 
cells in the presence of pep-
tides. QuantiWcation of spot-
forming T cells was done after 
16 h of incubation123
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patient LAU846 (HLA-A*2501, -A29, -B*0705, -B18)
were stimulated once in vitro with peptides derived
from MAGE-A3 and NY-ESO-1. Because LAU846
was HLA-A2-negative, peptides NY-ESO-1-ORF246–54
and MAGE-A3167–176 were selected. These two pep-
tides were previously shown to be naturally processed
and presented by HLA-B7 and HLA-B18, respectively
[22, 23]. Since B7 and B18 tetramers are not available,
stimulated T cells were tested in IFN- ELISPOT
assays, using as targets, peptide-pulsed autologous
cells. As shown in Fig. 3b, a signiWcant proportion of T
cells stimulated with MAGE-A3167–176 released IFN-
upon incubation with peptide-pulsed target cells. In
contrast, no response was detected after stimulation of
T cells with NY-ESO-1-ORF246–54 or an irrelevant
peptide. On the basis of this assay, the frequency of
MAGE-A3-speciWc T cells was estimated to be approx-
imately 1 in 104 CD8+ T cells.
Discussion
Our study shows that expression of CT genes, such as
MAGE-A3, -A4, -A10, SSX2 and NY-ESO-1, is infre-
quent in human CRC. In spite of this fact, evidence of
naturally acquired T cell responses could be demon-
strated in some of the patients expressing one or the
other CT antigens in their tumors.
A recent survey across various cancers revealed a
large disparity in the frequencies of CT gene expres-
sion. While melanoma, non-small cell lung carcinoma,
liver and bladder cancers frequently express products
of the MAGE family or NY-ESO-1, CRC, leukemias
and renal cancers rarely express these genes ([5] and
references therein). Our results conWrm these observa-
tions with respect to CRC. Interestingly, we found
more frequent expression of MAGE-A3 and MAGE-
A4 (13 and 15%, respectively) than any of the other
CT genes. A similar observation was also made by Li
et al. [16], who analyzed more than 100 CRC tissues for
the expression of CT genes. Despite this slightly more
frequent expression of MAGE-A3 and -A4, most CRC
lesions did not express any of the Wve CT genes tested
here. A possibility for this infrequent CT gene expres-
sion in CRC could be due to the stage of the tumor at
the time of resection. However, our analysis was per-
formed on tumors of diVerent TNM stages, ranging
from stage I to stage IV, and, on the basis of our sam-
pling, no correlation between the tumor stages and the
proWle of CT gene expression could be established.
Moreover, no increased frequency of CT genes expres-
sion was found among the 14 patients’ metastatic
tumors. Taken together, our results indicate that CT
gene neo-expression in CRC is unlikely to be caused by
epigenetic alterations during cancer progression such
as general demethylation [24, 25].
Immunohistochemical analyses of CT antigen-
positive CRC samples revealed weak expression of
MAGE-A in LAU846 and LAU852. By comparison,
strong staining of MAGE-A was detected in testicular
seminoma samples. This result suggests that the
expression level of MAGE-A gene products in CRC is
modest. However, it is possible that the weak staining
might be caused by the fact that the aYnity of mAb
57B and 6C1 against diVerent members of the MAGE-
A family varies signiWcantly [13]. Moreover, the pat-
tern of expression of the antigens within the lesions
was heterogeneous. While some tumor regions were
heavily stained, other regions were stained less or not
at all. This expression pattern is not unusual for CT
antigens and underscores the value of immunohisto-
chemical analyses as complement of the commonly
used PCR analyses [26, 27]. Indeed, RT-PCR being
generally performed on RNA extracted from heteroge-
neous tissue samples, detection of CT gene expression
by PCR might be misleading as the particular CT anti-
gen could be highly expressed in a small subset of cells
or, inversely, expressed at low levels in the majority of
cells. Such distinctions, which are all too often disre-
garded, are of critical importance for the development
of T cell vaccines against cancer.
Induction of spontaneous anti-tumor T cell
responses has been documented for a small number of
CT antigen-derived epitopes. Among those tested
here, NY-ESO-1 has been shown to be highly immuno-
genic and to elicit spontaneous T cell responses in
HLA-A2+ NY-ESO-1+ melanoma and breast cancer
patients [9, 28]. Despite the very limited number of
NY-ESO-1+ HLA-A2+ CRC patients identiWed in our
study, we nevertheless found a signiWcant frequency of
NY-ESO-1-speciWc T cells in the PBL of such patient.
This result shows for the Wrst time, to our knowledge,
that the expression of NY-ESO-1 in CRC can induce a
speciWc CD8+ T cell response. Unfortunately, further
phenotypic analyses of the speciWc T cells could not be
undertaken because the patient had chosen not to con-
tinue to participate in the study. Thus, no additional
blood sample was obtained. T cell response elicited by
peptide MAGE-A3167–176 was analyzed in a second
patient. Because of the HLA haplotype of this patient,
we selected a recently deWned MAGE-A3 epitope
restricted by HLA-B18 [23]. HLA-B18 is expressed in
approximately 11% of the Caucasian population [29].
In this case again, we could show that speciWc T cells
could be stimulated by peptide MAGE-A3167–176 to123
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remained low but suggested that appropriate vaccina-
tion strategies could be used to boost this response.
Taken together, our results indicate that CRC
expressing CT antigens can elicit antigen-speciWc T cell
responses, which could be boosted by active vaccina-
tion in a small subset of CRC patients. However, prior-
ity should be given to the search of frequently and
highly expressed CRC-associated antigens.
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